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We investigated common genetic variation in the entire ESR1 and EGF genes in relation to endometrial cancer risk, myometrial
invasion and endometrial cancer survival. We genotyped a dense set of single-nucleotide polymorphisms (SNPs) in both genes and
selected haplotype tagging SNPs (tagSNPs). The tagSNPs were genotyped in 713 Swedish endometrial cancer cases and 1567
population controls and the results incorporated into logistic regression and Cox proportional hazards models. We found five
adjacent tagSNPs covering a region of 15kb at the 50 end of ESR1 that decreased the endometrial cancer risk. The ESR1 variants did
not, however, seem to affect myometrial invasion or endometrial cancer survival. For the EGF gene, no association emerged between
common genetic variants and endometrial cancer risk or myometrial invasion, but we found a five-tagSNP region that covered 51kb
at the 50 end of the gene where all five tagSNPs seemed to decrease the risk of dying from endometrial cancer. One of the five
tagSNPs in this region was in strong linkage disequilibrium (LD) with the untranslated A61G (rs4444903) EGF variant, earlier shown
to be associated with risk for other forms of cancer.
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Endogenous and exogenous oestrogen exposure is a central
factor in the development and progression of endometrial
cancer (Persson, 2000), which is the most common gynaecological
cancer in the industrialised world. Oestrogen receptor a (ESR1) is
the main mediator of oestrogen effect in epithelium, including
the endometrium (Matsuzaki et al, 1999). The gene coding for
the ESR1 protein could thus play a role in susceptibility and
prognosis of endometrial cancer. Another potential role player in
endometrial cancer aetiology is the epidermal growth factor (EGF).
This protein can activate ESR1 and acts as a potent mitogen
for epithelial cells (Nelson et al, 1991; Ignar-Trowbridge et al, 1992;
Curtis et al, 1996; Dickson and Lippman, 1998; Marquez et al,
2001). We intended to study common variation in both the ESR1
(MIM 133430) and EGF (MIM 131530) genes in relation to
endometrial cancer risk, myometrial invasion and endometrial
cancer survival. The common variation in the EGF gene has
never before been investigated with regard to endometrial cancer
susceptibility, but a few studies have been published regarding
ESR1 and endometrial cancer risk (Weiderpass et al, 2000; Sasaki
et al, 2002; Iwamoto et al, 2003). The earlier investigators
have, however, concentrated only on few single-nucleotide
polymorphisms (SNPs) in the gene. We aimed towards cap-
turing the entire common variation in the ESR1 and EGF genes
by genotyping a dense set of markers in 92 Swedish controls and
then selecting haplotype tagging SNPs (tagSNPs) that were
genotyped in 713 Swedish endometrial cancer cases and 1567
Swedish controls. We assessed the association of the tagSNPs
with endometrial cancer risk, myometrial invasion and endo-
metrial cancer survival using logistic regression and Cox regres-
sion models.
MATERIALS AND METHODS
Study population and DNA extraction
Details of the population selection process for this study have been
published earlier (Einarsdottir et al, 2007). In brief, 68% (719) of
all endometrial cases among women 50–74 years of age identified
through the nation-wide cancer registries in Sweden between 1994
and 1995 agreed to participate in this study. During that period,
64% (1574) of the age-frequency matched controls selected from
the Swedish Registry of Total Population agreed to participate.
Only women with an intact uterus were considered eligible as
controls. All participants provided detailed questionnaire informa-
tion, and histological specimens for all the endometrial cases were
reviewed and re-classified by the study pathologist.
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donated whole blood for DNA extraction. For deceased cases
and those cases that declined to donate blood but consented to
our use of tissue, we collected archived paraffin-embedded, non-
cancerous tissue samples (n¼116). We extracted DNA from 4ml
of whole blood using the QIAamp DNA Blood Maxi Kit (Qiagen,
Solna, Sweden) according to the manufacturer0s instructions. From
non-malignant cells in paraffin-embedded tissue, we extracted
DNA using a standard phenol/chloroform/isoamyl alcohol proto-
col (Isola et al, 1994). We successfully isolated DNA from 600
(blood) and 116 (tissue) endometrial cancer patients and 1567
(blood) controls. We randomly selected 92 controls out of the 1567
controls to be used for linkage disequilibrium (LD) characterisa-
tion and haplotype reconstruction of the ESR1 and EGF genes.
This study was approved by the Institutional Review Boards in
Sweden and at the National University of Singapore.
SNP markers and genotyping
The ESR1 gene covers 295.7kb of genomic sequence on chromo-
some 6, and EGF spans 99.4kb on chromosome 4. We selected
SNPs in the ESR1 and EGF genes and their 20-kb flanking
sequences from dbSNP (build 124) and Celera databases, aiming
for an initial marker density of at least one SNP per 5kb. SNPs
were genotyped at the Genome Institute of Singapore using the
Sequenom primer extension-based assay (Sequenom, San Diego,
CA, USA) and the BeadArray system from Illumina (San Diego,
CA, USA) following the manufacturers’ instructions. All genotyp-
ing plates included positive and negative controls, DNA samples
were randomly assigned to the plates, and all genotyping results
were generated and checked by laboratory staff unaware of case–
control status. Only SNPs where 485% of the samples gave a
genotype call were analysed further. As quality control, we
genotyped 200 randomly selected SNPs in the 92 control samples
using both the Sequenom system and the BeadArray system. The
genotype concordance was 499.5%, suggesting high genotyping
accuracy and high concordance between the two platforms.
LD characterisation and TagSNP selection
We successfully genotyped 228 SNPs in the ESR1 gene and 104
SNPs in the EGF gene in the 92 controls. The SNP names, physical
positions, minor allele frequencies (MAF) and the Hardy–
Weinberg equilibrium (HWE) P-values have been published
earlier as Supplementary Tables 1 and 2 in Einarsdo ´ttir et al
(2008). We thereafter identified regions of LD and selected
‘tagging’ SNPs (tagSNPs). We produced LD plots of the D0 and
R
2 values for ESR1 and EGF using the LDheatmap function in the
statistical software R (Team, 2005). The plots have been published
earlier as Supplementary Figures 1 and 2 in Einarsdo ´ttir et al
(2008). We reconstructed haplotypes for the genes using the PLEM
algorithm (Qin et al, 2002) implemented in the tagSNPs program
(Stram et al, 2003) and selected tagSNPs based on the R
2
coefficient, which quantifies how well the tagSNP haplotypes
predict the SNPs or the number of copies of haplotypes an
individual carries. We chose tagSNPs so that common SNP
genotypes (minor allele frequency X0.03) and common haplo-
types (frequency X0.03) were predicted with R
2X0.8 (Gabriel
et al, 2002). The well-studied PvuII (rs2234693), XbaI (rs9340799),
codon 243 (rs4986934) and codon 325 (rs1801132) variants in
ESR1 had been genotyped earlier in our study subjects (Wedre ´n
et al, 2008), in both cases and controls, and were therefore ‘forced’
into the selection of tagSNPs. In order to evaluate our tagSNPs’
performance in capturing unobserved SNPs within the genes and
to assess whether we needed a denser set of markers, we carried
out an SNP-dropping analysis (Weale et al, 2003; Iles, 2006). In
brief, each of the genotyped SNPs was dropped in turn and
tagSNPs were selected from the remaining SNPs so that their
haplotypes predicted the remaining SNPs with an R
2 value of 0.85.
We then estimated how well the tagSNP haplotypes of the
remaining SNPs predicted the dropped SNP, an evaluation that
can provide an unbiased and accurate estimate of tagSNP
performance (Weale et al, 2003; Iles, 2006).
Endometrial tumour characteristics and follow-up
We retrieved information for the endometrial cancer cases on date
and cause of death until 31 December 2004 from the Swedish
Causes of Death Registry and on date of emigration from the
Swedish National Population Registry. Follow-up time began at
date of diagnosis and ended on 31 December 2004, or at the date of
death or emigration, whichever came first.
Endometroid endometrial carcinomas constituted the majority
of the cancers. The endometroid tumours were classified according
to cell differentiation: Grade I (well-differentiated carcinomas,
maximum 5% solid areas); Grade II (moderately differentiated,
6–50% solid areas); and Grade III (poorly differentiated or
undifferentiated, more than 50% solid areas). Myometrial invasion
was classified as present (at least 50% of the myometrial thickness
or through the serosa) or absent (none or o50% of the myometrial
thickness).
Statistical analyses
We applied unconditional logistic regression models for assessing
the association between ESR1 and EGF tagSNPs and risk of
endometrial cancer (case–control analysis) or myometrial inva-
sion (case-only analysis). Adjusting for age (in 5-year age groups)
did not affect our results. We estimated the hazard ratio (HR) of
death due to endometrial cancer in relation to the genes’ tagSNP
using Cox proportional hazards models. The tagSNPs were
included as covariates in the models either one at a time or in
groups of five (codominant main effects only). The latter method
was used for detection of association with haplotypes and is
referred to as the ‘sliding window’ analysis in the main text.
Although it does not require resolution of gametic phase, tests
based on such models can be powerful within regions of strong LD
(Clayton et al, 2004). Likelihood ratio tests were used to generate
P-values for comparing models with or without covariates.
Confounding has been defined as the presence of a common
cause to the exposure and the outcome (Hernan et al, 2002). We
believe that lifestyle and reproductive endometrial cancer risk
factors are unlikely to cause genetic variation and we thus did not
adjust for them in the analyses.
We made adjustments to our test results to account for
multiplicity. We did so for each outcome (risk, myometrial
invasion, and survival) separately. We used a permutation-based
approach that controls for the family-wise error rate (probability
of rejecting one or more true null hypotheses of no association).
Analyses were carried out using the statistical software R (Team,
2005) and the SAS system (release 9.1, SAS Institute Inc., Cary, NC,
USA).
RESULTS
Characteristics of participants
Table 1 shows selected characteristics of the study participants.
Statistically significant differences between cases and controls
reflected established associations.
Those cases who participated in our study through tissue sample
donation were on average 2.1 years older than the cases who
donated a blood sample (P¼0.002). The former group was also
more likely to have poorly differentiated (grade 3) tumours
(P¼0.08). As no significant differences in genotype frequencies
within Grade 1, Grade 2, and Grade 3 were evident between the two
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cause for concern.
Genotyping, LD pattern, and coverage
We selected a dense set of markers in the ESR1 and EGF genes for
genotyping in 92 randomly selected controls. We successfully
genotyped 228 SNPs in the ESR1 gene and 104 SNPs in the EGF
gene in the 92 controls. The SNP names, physical positions, MAF,
and HWE P-values have been published earlier as Supplementary
Tables 1 and 2 in Einarsdo ´ttir et al (2008). Summary statistics on
genotyping results and SNP coverage for the ESR1 and EGF genes
are shown in Table 2. Out of the SNPs successfully genotyped in
the 92 controls, those SNPs that conformed to HWE and that were
at least 3% in MAF were included in our study (Table 2). We thus
included 157 SNPs in ESR1 and 54 SNPs in EGF in our study for LD
mapping and tagSNP selection. The LD plots from the SNPs
included in our study have been published earlier as Supplemen-
tary Figures 1 and 2 in Einarsdo ´ttir et al (2008).
Using the SNP-dropping method (Weale et al, 2003), we assessed
the ability of the selected tagSNPs to capture variation in the SNPs
we did not genotype in our study. We found that the tagSNPs could
efficiently capture non-genotyped SNPs in the genes (Table 2).
Association analyses
We selected 52 tagSNPs in ESR1 and 15 tagSNPs in EGF that could
predict the SNPs included in our study and their haplotypes with
an R
2 of at least 0.8. The tagSNPs were genotyped in all cases and
controls (see Supplementary Table 1 for numbers as well as MAF
and HWE calculations), but seven tagSNPs in ESR1 and one
tagSNP in EGF could not be genotyped in the cases who
participated through tissue sample donation.
ESR1
P-values and odds ratios (ORs) for association of each tagSNP in
ESR1 with endometrial cancer risk, myometrial invasion and
endometrial cancer survival are presented in Figure 1,
Supplementary Figure 1, and Supplementary Figure 2, respectively.
The figures also show P-values (Pwin) generated from a sliding
window approach where five adjacent tagSNPs were analysed together
in a regression model (without resolution of gametic phase).
The single tagSNP analysis indicated a 15-kb region of five
tagSNPs – including TAG5 (rs3853250) to TAG9 (rs1709181) – that
were all associated with endometrial cancer risk (Figure 1), but
that did not withstand multiple testing correction. The sliding
window analysis including TAGs 5–9 gave a P-value of 0.072
(Figure 1). This region – which covered intron 1 and intron 2 at
the 50 end of ESR1 – included the PvuII (TAG6, OR 0.83, 95% CI
0.74–0.95) and XbaI (TAG7, OR 0.82, 95% CI 0.71–0.94) variants.
We show individual genotype associations for the five tagSNPs in
Table 3.
We reconstructed haplotypes from TAGs 5–9 and found that
five common (40.03) haplotypes accounted for 95% of the
chromosomes. We included expected ‘dosages’ of the five common
haplotypes and the rare haplotypes (combined into a single group)
as covariates in a logistic regression model with the most common
haplotype as reference (Stram et al, 2003). We found a haplotype
(haplotype 2) that carried all the five minor alleles of TAGs 5–9
was associated with endometrial cancer risk (P¼0.0026), com-
pared with haplotype 1, which carried none of the minor alleles
(Table 4). This association did not carry over to the global test
(P¼0.067).
The strongest signal in relation to endometrial cancer
risk (Figure 1) came from TAG12 (rs1033182, OR 0.82, 95% CI
0.72–0.94, P¼0.003) – situated 20kb from TAG9 – but this again
did not withstand adjustment for multiple testing (P¼0.154).
When we carried out the single tagSNP analyses within groups
defined by duration of menopausal oestrogen only use or family
history, we found that the protective effect of TAG12 on
endometrial cancer risk was to a large extent confined to never
users of menopausal oestrogen. Yet, the P-value for interaction did
not suggest that the effect of TAG12 depended on oestrogen only
use (P¼0.18).
Neither the single tagSNP analysis nor the window analysis
showed an association of common genetic variation in the ESR1
gene with myometrial invasion (Supplementary Figure 1) or
endometrial cancer survival (Supplementary Figure 2).
Table 2 Genotyping results and SNP coverage in ESR1 and EGF
ESR1 EGF
Successfully genotyped SNPs
a (n) 228
b 104
c
Polymorphic SNPs (n) 184 66
Common SNPs
d (n) 165 55
SNPs deviating from HWE
e (n)8 1
SNPs ultimately included in our study (n) 157 54
Gene size (kb) 295.7 99.4
Sequence coverage of included SNPs (kb) 335.1 145.5
Mean spacing between included SNPs (kb) 2.1 2.7
Median spacing between included SNPs (kb) 1.8 2.3
Number of tagSNPs selected 52 15
Average tagSNP prediction of common SNPs included in
study (R
2)
d
0.998 0.987
Coverage evaluation
f
Average prediction of dropped SNPs (R
2) 0.997 0.948
Percentage of R
2 values X0.7 100 96.3
EGF¼epidermal growth factor; HWE¼Hardy–Weinberg equilibrium; kb¼kilo
bases; SNPs¼single-nucleotide polymorphisms.
aIn 92 controls.
bSupplementary
Table 1 in Einarsdo ´ttir et al (2008).
cSupplementary Table 2 in Einarsdo ´ttir et al
(2008).
dCommon was defined as minor allele frequency X0.03.
ePo0.01.
fSNP
dropping method by Weale et al (2003).
Table 1 Selected characteristics of the cases and controls participating in
the present endometrial cancer study
Entire study
Cases/
controls (n)
Cases/controls
(mean) P
a
Age (years) 713/1567 64.0/62.8 o0.0001
Age at menopause (years) 624/1508 51.0/50.1 o0.0001
Recent BMI (kg/m
2)
b 712/1550 27.4/25.5 o0.0001
Age at last birth (years) 610/1408 29.4/30.4 0.0006
Parity 713/1567 1.9/2.1 o0.0001
Cases only n (%)
Endometrial
cancer deaths (n)
c
Mortality
rate
d
Total cases 713 41 0.0064
Endometroid tumours 661 (92.7) 30 0.0050
Grade 1 256 (38.7) 4 0.0017
Grade 2 289 (43.7) 13 0.0048
Grade 3 116 (17.6) 13 0.0134
Myometrial invasion
e
No 399 (70.5) 12 0.0034
Yes 167 (29.5) 11 0.0081
BMI¼body mass index.
aKruskal–Wallis test of difference between cases and
controls.
bOne year before diagnosis.
cFrom the date of diagnosis until 31 December
2004.
dFrom the date of diagnosis until 31 December 2004 or until date of
emigration, whichever came first. Calculated as endometrial cancer deaths per
person-year of follow-up.
eNo: No invasion or o50% of the myometrum. Yes:
Invasion through X50% of the myometrium or through the serosa.
ESR1 and EGF SNPs and endometrial cancer risk and survival
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Our data did not indicate that common genetic variants in the
EGF gene are associated with endometrial cancer risk (Supple-
mentary Figure 3) or myometrial invasion (Supplementary
Figure 4). With regard to endometrial cancer survival, the single
tagSNP analysis signified a 51-kb 50 region of five tagSNPs in
EGF – including TAG1 (rs718768, HR 0.42, 95% CI 0.22–0.81,
P¼0.0038) to TAG5 (rs1024600, HR 0.49, 95% CI 0.26–0.92,
P¼0.016) – that were associated with the risk of dying from
endometrial cancer (Figure 2). The association signals were,
however, rendered not significant after multiple testing adjust-
ment. The sliding window analysis including TAGs 1–5 gave a
P-value of 0.055 for endometrial cancer survival (Figure 2).
Table 3 shows individual genotype associations for the five
tagSNPs in EGF.
In this region of EGF, 10kb downstream of TAG1 and 2kb
upstream of TAG2 (rs881878), lies the untranslated A61G
(rs4444903) polymorphism. This polymorphism was genotyped
in our 92 Swedish controls and was in LD with TAG2 (R
2¼0.84).
TAG2 was associated with the risk of dying from endometrial
cancer with a HR of 0.57 (95% CI 0.33–0.97, P¼0.028).
tagSNP
TAG1
TAG2
TAG3
TAG4
TAG5
TAG6
TAG7
TAG8
TAG9
TAG10
TAG11
TAG12
TAG13
TAG14
TAG15
TAG16
TAG17
TAG18
TAG19
TAG20
TAG21
TAG22
TAG23
TAG24
TAG25
TAG26
P
0.641
0.28
0.617
0.047
0.015
0.005
0.003
0.009
0.006
0.37
0.517
0.003
0.784
0.802
0.95
0.013
0.66
0.837
0.567
0.191
0.693
0.789
0.866
0.759
0.954
0.314
Pwin
0.04
0.004
0.031
0.077
0.072
0.167
0.163
0.249
0.22
0.189
0.145
0.203
0.3
0.301
0.263
0.04
0.354
0.38
0.438
0.915
0.943
0.775
0.72
0.566
0.4 0.6 0.8 1.0 1.2 1.4 1.6
tagSNP
TAG27
TAG28
TAG29
TAG30
TAG31
TAG32
TAG33
TAG34
TAG35
TAG36
TAG37
TAG38
TAG39
TAG40
TAG41
TAG42
TAG43
TAG44
TAG45
TAG46
TAG47
TAG48
TAG49
TAG50
TAG51
TAG52
P
0.289
0.207
0.424
0.792
0.133
0.428
0.434
0.361
0.438
0.568
0.331
0.631
0.19
0.432
0.809
0.139
0.583
0.381
0.669
0.935
0.573
0.463
0.597
0.614
0.502
0.551
Pwin
0.31
0.794
0.452
0.341
0.182
0.296
0.551
0.933
0.703
0.717
0.539
0.225
0.32
0.143
0.621
0.669
0.8
0.84
0.943
0.899
0.786
0.771
0.748
0.678
0.6 0.8 1.0 1.2 1.4 1.6 1.8
Figure 1 Association of the 52 tagSNPs in ESR1 with endometrial cancer risk. Squares and horizontal lines represent odds ratios (change in risk with
each addition of the rare allele) and their confidence intervals. Sizes of the squares reflect the minor allele frequencies. P¼P-value for an association of each
tagSNP with endometrial cancer risk. Pwin¼P-value from a model including a window of five tagSNPs (the P-value aligns with the middle tagSNP of
each window) for an association with endometrial cancer risk.
Table 3 Genotype-specific associations of five tagSNPs in ESR1 and EGF with endometrial cancer risk and survival, respectively
ESR1 – endometrial cancer risk
TAG5 TAG6
a TAG7
b TAG8 TAG9
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
00 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
01 0.93 (0.75–1.14) 0.90 (0.74–1.11) 0.82 (0.68–0.99) 0.82 (0.68–0.99) 0.74 (0.60–0.90)
11 0.72 (0.55–0.93) 0.68 (0.53–0.89) 0.67 (0.49–0.92) 0.70 (0.51–0.97) 0.74 (0.57–0.97)
EGF – endometrial cancer survival
TAG1 TAG2 TAG3 TAG4 TAG5
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
00 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
01 0.39 (0.18–0.86) 0.70 (0.36–1.37) 0.73 (0.37–1.44) 0.76 (0.39–1.46) 0.52 (0.24–1.12)
11 0.23 (0.03–1.65) 0.17 (0.02–1.22) 0.17 (0.02–1.29) 0.25 (0.06–1.05) 0.20 (0.03–1.50)
CI¼confidence interval; EGF¼epidermal growth factor; HR¼hazard ratio; OR¼odds ratio.
aAlso named PvuII (rs2234693).
bAlso named XbaI (rs9340799).
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found that four common haplotypes (40.03) accounted for 95% of
the chromosomes in the cases. We constructed a Cox proportional
hazards model including the expected ‘dosages’ of the common
haplotypes and rare haplotypes (combined into a single group)
with the most common haplotype as reference (Table 4).
A haplotype (haplotype 2) carrying all rare alleles of the five
tagSNPs decreased the risk of dying from endometrial cancer
(P¼0.006, HR 0.33, 95% CI 0.15–0.73) compared with a haplotype
carrying none of the rare alleles. This association did not, however,
carry over to the global test (P¼0.10).
DISCUSSION
Using a comprehensive tagging approach of common variation in
the ESR1 and EGF genes, we assessed whether common variants in
the genes affected endometrial cancer risk, myometrial invasion,
or endometrial cancer survival. The ESR1 gene did not seem to
significantly affect myometrial invasion or endometrial cancer
survival. However, a 50 region of five tagSNPs in ESR1 decreased
endometrial cancer risk in our dataset. For the EGF gene, no
association emerged between common variants in the gene and
endometrial cancer risk or myometrial invasion, but we found a
five tagSNP region at the 50 end of the gene where all five tagSNPs
seemed to decrease the risk of dying from endometrial cancer. One
of the five tagSNPs in this region was in strong LD with the A61G
(rs4444903) EGF variant. None of the association signals in ESR1
or EGF withstood multiple testing correction.
Most earlier genetic association studies of the ESR1 gene in
relation to endometrial cancer risk have focused on only a few
common genetic polymorphisms. Among the most commonly
studied variants are the PvuII (TAG6, rs2234693), XbaI (TAG7,
rs9340799), codon 243 (TAG14, rs4986934) and codon 325
(TAG21, rs1801132) variants. Two groups that have explored both
the PvuII and XbaI variants in relation to endometrial cancer risk
(Weiderpass et al, 2000; Iwamoto et al, 2003) found that the
variants decreased the risk of the disease. However, a group that
investigated the PvuII, codon 243 and codon 325 variants found no
association with endometrial cancer risk (Sasaki et al, 2002). In our
earlier study of the ESR1 gene, we investigated the PvuII, XbaI,
codon 243, codon 325 variants, and a 50 promoter microsatellite
(rs2234670), and found the PvuII and XbaI variants as well as the
microsatellite to be associated with endometrial cancer risk
(Wedre ´n et al, 2008). In the current study, we went on to explore
the gene in greater detail and found a 50 region of five tagSNPs in
the ESR1 gene – including the PvuII (TAG6, rs2234693) and XbaI
(TAG7, rs9340799) variants – that decreased endometrial cancer
risk. It is interesting that, in our earlier publication of the ESR1
gene in relation to breast cancer risk and survival, the same region
showed a tendency towards a decreased risk of breast cancer
(Einarsdo ´ttir et al, 2008). Nevertheless, it is unlikely that any of
the SNPs genotyped within this region affect ESR1 protein
structure as none of them were located in exons. It is still a
possibility, however, that the SNPs themselves or one or more
SNPs in LD with any of them affect the regulation of ESR1 protein
expression. In fact, the PvuII variant has been suggested to
produce a functional binding site for the transcription factor
B-myb (Herrington et al, 2002).
This is the first study to explore the EGF gene in relation to
endometrial cancer risk and survival. We found five tagSNPs – one
upstream of the gene and the others in the 50 introns – that were
associated with the risk of dying from endometrial cancer. This
five-tagSNP region encompassed the 50 untranslated A61G
(rs4444903) polymorphism, which was in high LD with TAG2,
one of the five tagSNPs. The A61G variant has been found to affect
the risk of malignant melanoma (Shahbazi et al, 2002), hepato-
cellular carcinoma in patients with cirrhosis (Tanabe et al, 2008),
gastric cancer (Hamai et al, 2005; Jin et al, 2007), and glioma
(Costa et al, 2007). It has also been suggested to affect malignant
melanoma survival (Okamoto et al, 2006) and oesophageal cancer
survival (Jain et al, 2007). Furthermore, the 61*G allele has been
found to have a significantly more active promoter (Vauleon et al,
2007) and produce more EGF protein than the 61*A allele
(Shahbazi et al, 2002; Tanabe et al, 2008).
Our study was a population-based case–control study with a
well-defined study base. All participants were Caucasian and
born in Sweden between 1919 and 1944, at a time when foreign
immigration to Sweden was still rare (Statistics Sweden, 2004),
which means population stratification is of limited concern in our
study. Cases were ascertained from the nation-wide Swedish
Table 4 Association of haplotypes reconstructed from ESR1 TAGs 5–9
and EGF TAGs 1–5 with endometrial cancer risk and survival, respectively
ESR1 – risk Haplotype proportions
TAGs 5–9 Haplotypes
Cases
(n¼718
a)
Controls
(n¼1575
a) OR (95% CI)
Haplotype 1 00000 0.47 0.43 1.00 (Reference)
Haplotype 2 11111 0.26 0.29 0.79 (0.68–0.92)
Haplotype 3 11000 0.11 0.11 0.95 (0.77–1.18)
Haplotype 4 00001 0.09 0.08 0.91 (0.71–1.16)
Haplotype 5 11110 0.03 0.03 0.75 (0.50–1.13)
Rare
b 0.05 0.05 0.91 (0.67–1.24)
Global P-value
c 0.067
EGF – survival Haplotype proportions
Tags 1–5 Haplotypes Cases (n¼703
a) HR (95% CI)
Haplotype 1 00000 0.59 1.00 (Reference)
Haplotype 2 11111 0.23 0.33 (0.15–0.73)
Haplotype 3 01111 0.07 0.98 (0.45–2.16)
Haplotype 4 00010 0.06 0.86 (0.34–2.19)
Rare
d 0.05 0.70 (0.22–2.21)
Global P-value
c 0.10
CI¼confidence interval; EGF¼epidermal growth factor; HR¼hazard ratio;
OR¼odds ratio.
aInformation on at least one of the five tagSNPs.
b15 rare
haplotypes combined. Each haplotype has frequency below 3%.
cLikelihood ratio test.
d8 rare haplotypes combined. Each haplotype has frequency below 3%.
tagSNP
TAG1
TAG2
TAG3
TAG4
TAG5
TAG6
TAG7
TAG8
TAG9
TAG10
TAG11
TAG12
TAG13
TAG14
TAG15
P
0.004
0.028
0.04
0.041
0.016
0.735
0.728
0.025
0.089
0.716
0.32
0.067
0.58
0.627
0.176
Pwin
0.055
0.368
0.542
0.434
0.571
0.728
0.793
0.875
0.569
1
0.394
0.1 0.5 1.0 1.5 2.0 2.5
Figure 2 Association of the 15 tagSNPs in EGF with endometrial cancer
survival. Squares and horizontal lines represent hazard ratios (change in risk
with each addition of the rare allele) and their confidence intervals. Sizes of
the squares reflect the minor allele frequencies. P¼P-value for an
association of each tagSNP with endometrial cancer survival. Pwin¼
P-value from a model including a window of five tagSNPs (the P-value aligns
with the middle tagSNP of each window) for an association with
endometrial cancer survival.
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sCancer Registries, that contain virtually complete data on incident
cancers in Sweden (The Swedish National Board of Health and
Welfare, 2006). Information on date and cause of death of the cases
was obtained from the Causes of Death Registry in Sweden, which
has been found to be highly reliable (Nystrom et al, 1995). It is
therefore likely that there is little misclassification of the outcome.
Differential misclassification of the exposure is also unlikely to
have accounted for our results. Genotyping was carried out using
genotyping methods with low error rates, all genotyping plates
included positive and negative controls, DNA samples were
randomly assigned to the plates, and our genotyping personnel
were blinded to case–control status. We also replicated genotype
calls for a subset of samples using a separate genotyping method
with over 99.5% genotype concordance.
One limitation of our study was the relatively low participation
rates in our study and the small number of deaths included in the
survival analysis. The lack of participation may have been
associated with severe disease or death. In an attempt to minimise
the problem, we sought to obtain tissue samples from the deceased
cases and those cases that had declined donation of a blood
sample, and were able to obtain the majority of the samples
requested. It is thus unlikely that the relatively low participation
was related to genotype and we thus presume that the main
problem with regard to lack of participation and therefore low
number of deaths was decreased power in our study.
Another limitation that deserves mentioning is the fact that we
were unable to genotype seven tagSNPs in ESR1 and one tagSNP in
EGF in the tissue samples. In the case of these eight tagSNPs being
associated with severe disease, the association with risk of
endometrial cancer death might have been biased towards null in
our study because we could not genotype all the severe cases. None
of the eight tagSNPs were actually associated with endometrial
cancer survival in our study. The fact that the results were not
different when we restricted our analyses to the most severe cases
among those who donated blood samples indicates that the eight
tagSNPs were truly not associated with severe disease.
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